Prosecution Insights
Last updated: November 18, 2026
Application No. 18/741,328

B7-H4 ANTIBODY DOSING REGIMENS

Non-Final OA §102§DOUBLEPATENT
Filed
Jun 12, 2024
Priority
Feb 21, 2018 — provisional 62/633,527 +4 more
Examiner
ALSOMAIRY, SARAH ABDOALATIF
Art Unit
1646
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Five Prime Therapeutics Inc.
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
89%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
92 granted / 158 resolved
-1.8% vs TC avg
Strong +31% interview lift
Without
With
+31.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
37 currently pending
Career history
202
Total Applications
across all art units

Office Action

§102 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claim 1 is pending and currently under prosecution. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Kaplan et al (US 2019/0085080 A1; claiming priority date: 08/25/2017). The applied reference has a common Applicant with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Kaplan teaches a method of treating a solid tumor in a human subject, comprising administering to the subject 10-20 mg/kg of an antibody that specifically binds to B7-H4. Kaplan teaches that the antibody that binds to B7-H4 comprises a heavy chain variable region (VH) CDR1-3 which match 100% to the instantly claimed SEQ ID Nos: 5-6-7, respectively, and a light chain variable region (VL) CDR-1-3 which match 100% to the instantly claimed SEQ ID Nos: 8-9-10, respectively. [see sequence alignments below] [0359-0365, 0375; Tables 3 and 4] SEQUENCE ALIGNMENTS SEQ ID NOS: 5-6-7 RESULT 1 US-16-111-064-464 (NOTE: this sequence has 8 duplicates in the database searched) Sequence 464, US/16111064 Patent No. 11306144 GENERAL INFORMATION APPLICANT: FIVE PRIME THERAPEUTICS, INC. TITLE OF INVENTION: B7-H4 Antibodies and Methods of Use Thereof FILE REFERENCE: 3986.0090004 CURRENT APPLICATION NUMBER: US/16/111,064 CURRENT FILING DATE: 2018-08-23 PRIOR APPLICATION NUMBER: 62/550,173 PRIOR FILING DATE: 2017-08-25 PRIOR APPLICATION NUMBER: 62/579,774 PRIOR FILING DATE: 2017-10-31 PRIOR APPLICATION NUMBER: 62/607,810 PRIOR FILING DATE: 2017-12-19 PRIOR APPLICATION NUMBER: 62/656,789 PRIOR FILING DATE: 2018-04-12 NUMBER OF SEQ ID NOS: 469 SEQ ID NO 464 LENGTH: 120 TYPE: PRT ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Antibody 20502 Variable Heavy Chain Query Match 88.9%; Score 194.6; Length 120; Best Local Similarity 47.0%; Matches 39; Conservative 0; Mismatches 0; Indels 44; Gaps 2; Qy 1 GSIKSGSYYW--------------GNIYYSGSTYYNPSLRS------------------- 27 |||||||||| ||||||||||||||||| Db 27 GSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSS 86 Qy 28 -----------AREGSYPNQFDP 39 |||||||||||| Db 87 VTAADTAVYYCAREGSYPNQFDP 109 SEQ ID NOS: 8-9-10 RESULT 1 US-16-111-064-12 (NOTE: this sequence has 17 duplicates in the database searched) Sequence 12, US/16111064 Patent No. 11306144 GENERAL INFORMATION APPLICANT: FIVE PRIME THERAPEUTICS, INC. TITLE OF INVENTION: B7-H4 Antibodies and Methods of Use Thereof FILE REFERENCE: 3986.0090004 CURRENT APPLICATION NUMBER: US/16/111,064 CURRENT FILING DATE: 2018-08-23 PRIOR APPLICATION NUMBER: 62/550,173 PRIOR FILING DATE: 2017-08-25 PRIOR APPLICATION NUMBER: 62/579,774 PRIOR FILING DATE: 2017-10-31 PRIOR APPLICATION NUMBER: 62/607,810 PRIOR FILING DATE: 2017-12-19 PRIOR APPLICATION NUMBER: 62/656,789 PRIOR FILING DATE: 2018-04-12 NUMBER OF SEQ ID NOS: 469 SEQ ID NO 12 LENGTH: 107 TYPE: PRT ORGANISM: Artificial Sequence FEATURE: OTHER INFORMATION: Antibody 15461 Variable Light Chain Query Match 81.6%; Score 109.3; Length 107; Best Local Similarity 36.5%; Matches 27; Conservative 0; Mismatches 0; Indels 47; Gaps 2; Qy 1 RASQSVSSNLA---------------GASTRAT--------------------------- 18 ||||||||||| ||||||| Db 24 RASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDF 83 Qy 19 -----QQYHSFPFT 27 ||||||||| Db 84 AVYYCQQYHSFPFT 97 Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 and 8 of U.S. Patent No. 11,306,144 in view of Liu et al (US9676854 B2; Published 2014). The U.S. Patent claims a method of treating a solid tumor comprising administering an antibody that specifically binds to B7-H4, comprising the instantly claimed sequences. However, The U.S. Patent does not claim the wherein the B7-H4 antibody is administered at a dose of about 0.005 to about 20 mg/kg. Liu teaches the method of treating cancer comprising administering an antibody that binds to B7-H4, wherein the B7-H4 antibody is administered to the subject at doses ranging from 0.005 mg/kg and 20 mg/kg. [Col. 46 lines 39-62] It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to treat solid tumors with administration of a B7-H4 antibody at a dose of about 0.005 to about 20 mg/kg. One would have been motivated to because the U.S. Patent and Liu teach and claim treating subjects having B7-H4 expressing tumors by administering the B7-H4 antibody. One of ordinary skill in the art would have reasonable expectation of success because Liu teaches and suggests administering B7-H4 antibody for cancer treatment at a dose of about 0.005 to about 20 mg/kg, for the same purpose to treat cancer as claimed by the U.S. Patent. Claims 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 5, and 12 of U.S. Patent No. 11,814,431 in view of Liu et al (US9676854B2; Published 2014). The U.S. Patent claims a method of treating a solid tumor comprising administering an antibody that specifically binds to B7-H4, comprising the instantly claimed sequences. However, the U.S. Patent does not claim the wherein the B7-H4 antibody is administered at a dose of about 0.005 to about 20 mg/kg. Liu teaches the method of treating cancer comprising administering an antibody that binds to B7-H4, wherein the B7-H4 antibody is administered to the subject at doses ranging from 0.005 mg/kg and 20 mg/kg. [Col. 46 lines 39-62] It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was filed to treat solid tumors with administration of a B7-H4 antibody at a dose of about 0.005 to about 20 mg/kg. One would have been motivated to because the U.S. Patent and Liu teach and claim treating subjects having B7-H4 expressing tumors with the B7-H4 antibody. One of ordinary skill in the art would have reasonable expectation of success because Liu teaches and suggests administering B7-H4 antibody for cancer treatment at a dose of about 0.005 to about 20 mg/kg for the same purpose to treat cancer, as claimed by the U.S. Patent. Conclusion Conclusion: Claim 1 is rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH A ALSOMAIRY whose telephone number is (571)272-0027. The examiner can normally be reached Monday-Friday 7:30 AM to 5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory Emch can be reached at (571) 272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH A ALSOMAIRY/ Examiner, Art Unit 1646
Read full office action

Prosecution Timeline

Jun 12, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702702
APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA
1y 2m to grant Granted Aug 11, 2026
Patent 12698343
COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
4y 2m to grant Granted Aug 04, 2026
Patent 12692518
THERAPEUTIC GENOME EDITING IN WISKOTT-ALDRICH SYNDROME AND X-LINKED THROMBOCYTOPENIA
3y 3m to grant Granted Jul 28, 2026
Patent 12667606
FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE
4y 9m to grant Granted Jun 30, 2026
Patent 12668644
ANTIBODY-BASED METHOD TO IDENTIFY, PURIFY, AND MANIPULATE CELL TYPES AND PROCESSES
4y 7m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
89%
With Interview (+31.0%)
Low
PTA Risk
Based on 158 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month